VXRT News and Press, Vaxart Inc. From 05/14/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Is now the time to take a look at speculative Covid-19 play Vaxart (NASDAQ: VXRT ) stock? The clinical-stage biotech name has been at work on an oral coronavirus vaccine since before Covid-19 was declared a pandemic ...

Vaxart (VXRT), a clinical-stage biotech company, has made advances in developing a multivariant oral COVID-19 vaccine candidate. However, given that the vaccine candidate is still undergoing Phase I and Phase 2 clinical trials at a time when VXRT’s peers have long ago launched their va...

In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. The stock subsequently soared to a multiyear high of $24.90 per share in February, becoming a ten-bagger over a 1...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips An oral Covid-19 vaccine is, plain and simple, a great idea. Clinical-stage biotechnology company Vaxart  (NASDAQ: VXRT ) offers an alternative to inconvenient and uncomfortable injections. And so, you’d th...

Shares of vaccine expert Vaxart (NASDAQ: VXRT) have gone on a wild ride over the past 12 months as the company has released data for its coronavirus vaccine. In this video from Motley Fool Live , recorded on April 5 , Fool.com Contributors Brian Orelli and Keith Spei...

Vaxart (VXRT) has enrolled the first subject in a Phase 1b trial, VXA-NVV-104, evaluating safety and immunogenicity of oral norovirus vaccine in elderly subjects aged 55 – 80 years. The study drug will be an oral tablet administered on Days 1 and 29. “The norovirus program ...

Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine Safety and immunogenicity data to also inform oral COVID-19 vaccine program in...

Even with three COVID-19 vaccines already on the market in the U.S., the scramble to develop better vaccines is far from over. Ocugen (NASDAQ: OCGN) and Vaxart (NASDAQ: VXRT) stand out as two small companies hoping to achieve success. Vaxart's shares skyrocketed more tha...

James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...

If you've ever ordered a piping hot pizza to your door, you already know that convenience is king. It's no secret that people are willing to pay for products that make their lives easier or less painful. But does that same principle hold up for products that consumers uniformly expect to be...